stoxline Quote Chart Rank Option Currency Glossary
  
GlycoMimetics, Inc. (GLYC)
15.705  -0.445 (-2.76%)    07-02 15:58
Open: 16.25
High: 17.3899
Volume: 612
  
Pre. Close: 16.15
Low: 15.515
Market Cap: 1,013(M)
Technical analysis
2025-07-17 8:15:34 AM
Short term     
Mid term     
Targets 6-month :  26.6 1-year :  32.11
Resists First :  22.78 Second :  27.5
Pivot price 17.59
Supports First :  15.14 Second :  12.6
MAs MA(5) :  16.28 MA(20) :  18.55
MA(100) :  23.58 MA(250) :  24.14
MACD MACD :  -2 Signal :  -1.8
%K %D K(14,3) :  12.5 D(3) :  15.2
RSI RSI(14): 30.8
52-week High :  63 Low :  0.26
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GLYC ] has closed above bottom band by 23.1%. Bollinger Bands are 31.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 17.5 - 17.67 17.67 - 17.77
Low: 15.19 - 15.39 15.39 - 15.51
Close: 15.47 - 15.8 15.8 - 16
Company Description

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Headline News

Thu, 05 Jun 2025
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals - Business Wire

Tue, 06 May 2025
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – GLYC, BRZH, PRA, FVNNU - Morningstar

Tue, 29 Apr 2025
GlycoMimetics Amends Merger Agreement With Crescent Biopharma - Investing.com

Fri, 14 Feb 2025
GlycoMimetics adjusts merger terms with Crescent Biopharma - Investing.com

Thu, 13 Feb 2025
GLYCOMIMETICS INC SEC 10-K Report - TradingView

Tue, 12 Nov 2024
Crescent Biopharma to Showcase Cancer Drug Pipeline at Jefferies Healthcare Conference - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 65 (M)
Shares Float 1 (M)
Held by Insiders 2.6 (%)
Held by Institutions 47.7 (%)
Shares Short 17 (K)
Shares Short P.Month 18 (K)
Stock Financials
EPS -46
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.23
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -74 %
Return on Equity (ttm) -182.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.37
Qtrly Earnings Growth 0 %
Operating Cash Flow -26 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio -0.35
PEG Ratio 0
Price to Book value 3
Price to Sales 0
Price to Cash Flow -39.44
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android